DACHF

Daicel Corporation

DACHF, USA

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photoresists, optical lenses, and caprolactone derivatives; functional films and materials used in smartphones, PCs, TVs, and in-vehicle displays, polymers and solvents; and lenses used in VR, smartphones and various sensors. In addition, the company offers airbags inflators, pyro-fuses, and gas generators for seat belt pretensioners; acetic acid, acetic acid derivatives, acetate tow, ketene / diketene derivatives, cellulose acetate for LCD optical films, amines, and 1,3-butylene glycol; and reverse osmosis membrane and ultrafiltration membrane products, as well as water treatment systems. Further, it provides Engineering plastics comprising polyacetal, polybutylene terephthalate, polyphenylene sulfide, liquid crystal polymer, and cyclic olefin copolymer; AS resin, acetate plastics, water-soluble polymers, and barrier films for packaging; ABS resins, various polymer alloys, plastic compounds; Polyamide-12 and PEEK resin; and various molded containers. The company's products are used in transportation, electronics, medical care, personal care, everyday life, and environment and energy applications. The company was formerly known as Daicel Chemical Industries, Ltd. and changed its name to Daicel Corporation in October 2011. Daicel Corporation was incorporated in 1919 and is headquartered in Osaka, Japan.

https://www.daicel.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

Semiannual

Rate:

0.203

Next Payout:

Jun 1, 2026

Yield:

9.6209 %

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

9.70

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

0.87

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

2.42 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

0.01 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

1.20

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Daicel Corporation

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

52.31

Latest Release

Date

2025-09-30

EPS Actual

0.2347

EPS Estimate

66.49

EPS Difference

-66.2553

Surprise Percent

-99.647%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(2.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1.5)
Momentum
Strong Momentum(8)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Moderate Quality(4)
Value
Undervalued(7)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.